Drug Trial Radar · NCT07425535
Optic Nerve Head Strain in Non-glaucoma Subjects
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 24, 2026
Primary completion
Mar 1, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Eye Institute (NEI)
- First posted
- Feb 23, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 90 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Persons who do not have glaucoma will have pictures taken of the optic nerve with a standard camera before and 2 weeks after starting to take a daily glaucoma eye drop to lower eye pressure. These data will be used to compare to the same procedure performed with glaucoma patients to study how glaucoma injures the eye.
Conditions
- Glaucoma
Interventions
Latanoprost (0.005%)Drug
Participants take the eye drop daily for less than one month
Primary outcomes
What the sponsor says the trial is designed to measure.
- Optic nerve head strainTime frame: up to 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Johns Hopkins Hospital
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.